Leah Kuntz

Stay informed with this week's highlights in psychiatric advancements, including emergency psychiatry, a major update on Cobenfy, new partnerships for better treatments, and more.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

Explore key updates in psychiatric health, including Black maternal health, self-harm insights, schizophrenia treatment advancements, and expert interviews.

About 40% of women who have postpartum depression go unrecognized and untreated, and they are still symptomatic 3 years later.

Does trontinemab represent the next generation of anti-amyloid monoclonal antibodies thanks to Brainshuttle technology? New research looks encouraging.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Do you want to be featured in a future Special Report? Check out our April theme!

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.

Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.

Alzamend announced a late 2025 initiation for the phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder.

March 17 through March 23 is National Drug and Alcohol Facts Week 2025.

A one-size-fits-all approach does not work—each mother’s experience with postpartum depression is unique.

Neurocrine Biosciences has initiated a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1140675 for certain neurological and neuropsychiatric conditions, such as tardive dyskinesia.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

Pipeline drug BHV-7000 failed to meet primary endpoint in a pivotal phase 2/3 trial for bipolar disorder; meanwhile, BHV-1300 sees success in sustained Reductions in Total IgG.

Vincenzo Di Nicola has won the Award for Leadership in Child, Adolescent, and Young Adult Psychiatry. Learn more about his thoughts on trauma, leadership, and issues in child and adolescent psychiatry.

Do you want to be featured in a future Special Report? Check out our March theme!

The president of Black Psychiatrists of America shares his thoughts on making a difference for Black communities, the removal of the REMS for clozapine, and more.

Check out the pipeline updates from February!

Newly shared top-line phase 4 data demonstrates clinically meaningful and sustained effects of Ingrezza capsules on the physical, social, and emotional impacts experienced with tardive dyskinesia.

The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

The FDA has authorized key modifications to the administration protocol for injectable long-acting opioid use disorder treatment buprenorphine.